Tag Archives: Reni Benjamin

Verastem (VSTM) Received its Third Buy in a Row

After Roth Capital and H.C. Wainwright gave Verastem (NASDAQ: VSTM) a Buy rating last month, the company received another Buy, this time from Raymond James. Analyst Reni Benjamin maintained a Buy rating on Verastem today and set a price target

MacroGenics (MGNX) Gets a Sell Rating from Raymond James

In a report issued on January 18, Reni Benjamin from Raymond James maintained a Sell rating on MacroGenics (MGNX – Research Report). The company’s shares closed on Friday at $12.31, close to its 52-week low of $11.16. According to TipRanks.com,

Raymond James Reiterates Their Buy Rating on Incyte Corp (INCY)

Raymond James analyst Reni Benjamin reiterated a Buy rating on Incyte Corp (NASDAQ: INCY) today. The company’s shares opened today at $64.29, close to its 52-week low of $60.23. Benjamin commented: “We are reiterating our Strong Buy rating for Incyte.

Analysts Have Conflicting Sentiments on These Healthcare Companies: ADMA Biologics (NASDAQ: ADMA) and Bristol Myers (NYSE: BMY)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on ADMA Biologics (NASDAQ:ADMA) and Bristol Myers (NYSE:BMY). ADMA Biologics (ADMA) In a report released today, Reni Benjamin from Raymond James maintained a Buy rating on

Raymond James Sticks to Their Buy Rating for Spark Therapeutics (ONCE)

Raymond James analyst Reni Benjamin maintained a Buy rating on Spark Therapeutics (NASDAQ: ONCE) today. The company’s shares opened today at $57.86. Benjamin observed: “We are maintaining our Outperform rating for shares of ONCE. This morning the E.U.’s Committee for

Analysts’ Top Healthcare Picks: Incyte Corp (INCY), Alexion Pharmaceuticals (ALXN)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Incyte Corp (NASDAQ:INCY), Alexion Pharmaceuticals (NASDAQ:ALXN) and Icon plc (NASDAQ:ICLR) with bullish sentiments. Incyte Corp (INCY) In a report released yesterday, Reni